OnkoSight Advanced NGS Rapid AML Panel OnkoAML

Synonyms

Allscripts (AEHR) Order Name

OnkoSight NGS AML Panel

Sunrise Clinical Manager (SCM) Order Name

OnkoSight NGS AML Panel

EPIC Order Name

OnkoSight NGS AML Panel

Clinical Info

Tumor sequencing by NGS detecting mutations in 30 genes associated with AML. Mutations often have prognostic significance, may confer 
resistance to FDA approved therapies, or may qualify patients for late-stage clinical trials.

Specimen Type

Blood, Bone Marrow

Specimen Volume

Container

Lavender Top Tube

Collection Instructions

Container/Tube: Lavender top tube
Specimen: 2 mL Bone Marrow or Whole Blood
Alternate Specimens: Bone Marrow - Green Top, Peripheral Blood - Lavender Top,
Peripheral Blood - Green Top, Eppendorf tube, Unstained Slide, Formalin-fixed,
Paraffin-embedded Tissue
Decalcified specimens are not recommended for NGS testing.
Note: Please indicate specimen type

Transport Instructions

Room Temperature

Specimen Stability

30 Days Room Temperature or Refrigerated

Methodology

Genotyping by Next Generation Sequencing
Gene:
ASXL1BRAFBCORCEBPACSFR3DDX41DNMT3AETV6EZH2FLT3GATA2HRASIDH1IDH2JAK2KITKMT2AKRASNF1NPM1NRASPDGFRAPHF6PTPN11RUNX1SETBP1STAG2TET2TP53WT

Days Performed

TAT: 10 - 12 Days

Performing Laboratory

GenPath BioReference
Test Code: TL94

CPT

81450

PDM

1659925

Result Interpretation

See Report

Forms


edit